Cargando…

Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome

PURPOSE: This study aimed to develop a utility index (the ABC-UI) from the Aberrant Behavior Checklist-Community (ABC-C), for use in quantifying the benefit of emerging treatments for fragile X syndrome (FXS). METHODS: The ABC-C is a proxy-completed assessment of behaviour and is a widely used measu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerr, Cicely, Breheny, Katie, Lloyd, Andrew, Brazier, John, Bailey, Donald B., Berry-Kravis, Elizabeth, Cohen, Jonathan, Petrillo, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317522/ https://www.ncbi.nlm.nih.gov/pubmed/25063082 http://dx.doi.org/10.1007/s11136-014-0759-8

Ejemplares similares

Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)

Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements
por: Nixon, Annabel, et al.
Publicado: (2013)

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2012)

Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
por: Farzin, Faraz, et al.
Publicado: (2011)

Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
por: Alusi, Ghassan, et al.
Publicado: (2022)

A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome
por: Lee, Michelle, et al.
Publicado: (2016)

Fragile X checklists: A meta‐analysis and development of a simplified universal clinical checklist
por: Lubala, Toni Kasole, et al.
Publicado: (2018)

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
por: Lee, Anna W., et al.
Publicado: (2018)

Erratum to: A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome
por: Lee, Michelle, et al.
Publicado: (2017)

Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2020)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Utility of the Hebb–Williams Maze Paradigm for Translational Research in Fragile X Syndrome: A Direct Comparison of Mice and Humans
por: Boutet, Isabelle, et al.
Publicado: (2018)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

X-inactivation in the clinical phenotype of fragile X premutation carrier sisters
por: Hall, Deborah A., et al.
Publicado: (2016)

New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype
por: Fraint, Avram, et al.
Publicado: (2014)

Open-label add-on treatment trial of minocycline in fragile X syndrome
por: Paribello, Carlo, et al.
Publicado: (2010)

Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment
por: Hoffmann, Anne, et al.
Publicado: (2020)

Vocabulary comprehension in adults with fragile X syndrome (FXS)
por: Hoffmann, Anne, et al.
Publicado: (2019)

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities
por: Weber, Jayne Dixon, et al.
Publicado: (2019)

Expression and Characterization of Human Fragile X Mental Retardation Protein Isoforms and Interacting Proteins in Human Cells
por: Zhang, Jiang, et al.
Publicado: (2019)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Profiles of aberrant white matter microstructure in fragile X syndrome
por: Hall, Scott S., et al.
Publicado: (2016)

ASFMR1 splice variant: A predictor of fragile X-associated tremor/ataxia syndrome
por: Vittal, Padmaja, et al.
Publicado: (2018)

Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS)
por: Knox, Andrew, et al.
Publicado: (2012)

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
por: Budimirovic, Dejan B., et al.
Publicado: (2017)

Examination of Correlates to Health-Related Quality of Life in Individuals with Fragile X Syndrome
por: Coffman, Marika C., et al.
Publicado: (2020)

Aberrant DNA Methylation of ABC Transporters in Cancer
por: Zappe, Katja, et al.
Publicado: (2020)

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome
por: Hessl, David, et al.
Publicado: (2019)

Tremorography in fragile X-associated tremor/ataxia syndrome, Parkinson's disease and essential tremor
por: Robertson, Erin E., et al.
Publicado: (2020)

Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
por: Lozano, Reymundo, et al.
Publicado: (2022)

Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)
por: Hall, Deborah A., et al.
Publicado: (2020)

Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2021)

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
por: Bailey, Donald B., et al.
Publicado: (2015)

Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study
por: Brašić, James Robert, et al.
Publicado: (2022)

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
por: Berry-Kravis, E, et al.
Publicado: (2009)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
por: Hagerman, Randi, et al.
Publicado: (2018)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ov9ofn6j8glo4j1taonn38kbg7